CN104127737A - 用于防治痔疮术后并发症的药物组合物及其制备方法 - Google Patents
用于防治痔疮术后并发症的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN104127737A CN104127737A CN201410403174.2A CN201410403174A CN104127737A CN 104127737 A CN104127737 A CN 104127737A CN 201410403174 A CN201410403174 A CN 201410403174A CN 104127737 A CN104127737 A CN 104127737A
- Authority
- CN
- China
- Prior art keywords
- herba
- weight portions
- weight portion
- weight
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000014617 hemorrhoid Diseases 0.000 title claims abstract description 46
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 208000035965 Postoperative Complications Diseases 0.000 title claims abstract description 26
- 230000003405 preventing effect Effects 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 92
- 239000000463 material Substances 0.000 claims abstract description 40
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 24
- 240000003296 Petasites japonicus Species 0.000 claims abstract description 18
- 235000003823 Petasites japonicus Nutrition 0.000 claims abstract description 18
- 239000000454 talc Substances 0.000 claims abstract description 13
- 229910052623 talc Inorganic materials 0.000 claims abstract description 13
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- 239000000843 powder Substances 0.000 claims description 53
- 241000628997 Flos Species 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 34
- 239000013521 mastic Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 25
- 206010058046 Post procedural complication Diseases 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- 238000001356 surgical procedure Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 21
- 210000000582 semen Anatomy 0.000 claims description 20
- 241000208152 Geranium Species 0.000 claims description 18
- 239000009636 Huang Qi Substances 0.000 claims description 18
- 241000218176 Corydalis Species 0.000 claims description 16
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 241001250596 Pleione Species 0.000 claims description 14
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 13
- 239000002674 ointment Substances 0.000 claims description 13
- 235000006226 Areca catechu Nutrition 0.000 claims description 12
- 241001057584 Myrrha Species 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 235000012222 talc Nutrition 0.000 claims description 12
- 244000025254 Cannabis sativa Species 0.000 claims description 11
- 244000080767 Areca catechu Species 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 229940040145 liniment Drugs 0.000 claims description 9
- 239000000865 liniment Substances 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 229960004793 sucrose Drugs 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 239000011265 semifinished product Substances 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000007766 cera flava Substances 0.000 claims description 3
- 238000003113 dilution method Methods 0.000 claims description 3
- 229940053652 fluorinse Drugs 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 3
- 229940099259 vaseline Drugs 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 abstract description 55
- 230000036407 pain Effects 0.000 abstract description 55
- 230000000694 effects Effects 0.000 abstract description 53
- 210000004369 blood Anatomy 0.000 abstract description 43
- 239000008280 blood Substances 0.000 abstract description 43
- 230000008961 swelling Effects 0.000 abstract description 25
- 231100000331 toxic Toxicity 0.000 abstract description 10
- 230000002588 toxic effect Effects 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 4
- 241001145009 Sophora alopecuroides Species 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 240000004704 Desmodium gangeticum Species 0.000 abstract 1
- 241001090156 Huperzia serrata Species 0.000 abstract 1
- 244000083012 Ipomoea cairica Species 0.000 abstract 1
- 241000245240 Lonicera Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 description 31
- 206010007247 Carbuncle Diseases 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 230000006870 function Effects 0.000 description 23
- 239000003440 toxic substance Substances 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 210000002216 heart Anatomy 0.000 description 17
- 206010017553 Furuncle Diseases 0.000 description 16
- 206010030113 Oedema Diseases 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 210000003205 muscle Anatomy 0.000 description 15
- 208000006820 Arthralgia Diseases 0.000 description 14
- 235000009508 confectionery Nutrition 0.000 description 14
- 208000001848 dysentery Diseases 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- 230000003203 everyday effect Effects 0.000 description 12
- 230000001717 pathogenic effect Effects 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 206010040943 Skin Ulcer Diseases 0.000 description 10
- 241000411851 herbal medicine Species 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 231100000019 skin ulcer Toxicity 0.000 description 10
- 230000008736 traumatic injury Effects 0.000 description 10
- 208000004880 Polyuria Diseases 0.000 description 9
- 208000025865 Ulcer Diseases 0.000 description 9
- 230000035619 diuresis Effects 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- 241000700199 Cavia porcellus Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000003026 hypopharynx Anatomy 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 210000000436 anus Anatomy 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000002574 poison Substances 0.000 description 7
- 230000001047 pyretic effect Effects 0.000 description 7
- 208000008454 Hyperhidrosis Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 201000007227 lymph node tuberculosis Diseases 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 239000002435 venom Substances 0.000 description 6
- 210000001048 venom Anatomy 0.000 description 6
- 231100000611 venom Toxicity 0.000 description 6
- 206010003011 Appendicitis Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 206010023126 Jaundice Diseases 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 208000033809 Suppuration Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 208000002399 aphthous stomatitis Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 208000003512 furunculosis Diseases 0.000 description 5
- 210000000629 knee joint Anatomy 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 208000015220 Febrile disease Diseases 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 206010021118 Hypotonia Diseases 0.000 description 4
- 208000015817 Infant Nutrition disease Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 208000017561 flaccidity Diseases 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 201000000297 Erysipelas Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011262 co‐therapy Methods 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 201000007772 internal hemorrhoid Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000003453 lung abscess Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 230000001617 migratory effect Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 206010042772 syncope Diseases 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 235000014101 wine Nutrition 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 244000235603 Acacia catechu Species 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000016583 Anus disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RFKQJTRWODZPHF-UHFFFAOYSA-N Dehydrocorydaline Chemical compound COC1=C(OC)C=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(C)=C3C2=C1 RFKQJTRWODZPHF-UHFFFAOYSA-N 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000402754 Erythranthe moschata Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000037319 Hepatitis infectious Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241001448624 Miliaria Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010034038 Parotitis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000003639 vasoconstrictive effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 description 1
- 241001533451 Ajuga ciliata Species 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 244000089795 Clausena lansium Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 206010016029 Face oedema Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- MAYJEFRPIKEYBL-OASIGRBWSA-N Obacunone Chemical compound C=1([C@@H]2OC(=O)[C@H]3O[C@@]43[C@]3(C)C(=O)C[C@H]5C(C)(C)OC(=O)C=C[C@]5(C)[C@H]3CC[C@]42C)C=COC=1 MAYJEFRPIKEYBL-OASIGRBWSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 206010038074 Rectal polyp Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 description 1
- 241001643409 Sinomenium acutum Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000003796 chancre Diseases 0.000 description 1
- 210000000080 chela (arthropods) Anatomy 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000003664 filaricide agent Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940105040 geranium extract Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- BCZFSDNVXODRAJ-JTTNIQEDSA-N lycopodine Chemical compound C1CCN2CCC[C@@H]3[C@H]4C[C@@H](C)C[C@]32[C@H]1C(=O)C4 BCZFSDNVXODRAJ-JTTNIQEDSA-N 0.000 description 1
- BCZFSDNVXODRAJ-ZHMBSYLPSA-N lycopodine Natural products C1CCN2CCC[C@@H]3[C@H]4C[C@H](C)C[C@]32[C@H]1C(=O)C4 BCZFSDNVXODRAJ-ZHMBSYLPSA-N 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- -1 methyl pentose Chemical class 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- VSLDMVSILHVDSR-UHFFFAOYSA-N obacunone Natural products CC1(C)OC(=O)C=CC2(C)C1CC(=O)C3(C)C2CCC4(C)C(OC(=O)C5OC345)c6occc6 VSLDMVSILHVDSR-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 208000022075 polyp of rectum Diseases 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229930002966 sinomenine Natural products 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于防治痔疮术后并发症的药物组合物及其制备方法,其中药物组合物包括外用药物和内服药物,外用药物包括以下原料药材:滑石、苦豆子、儿茶、金银花、千层塔、四叶草、白芍、五爪金龙、没药、蜂斗菜、粘人草和冰片。本发明的有益效果是:本发明药物组合物包括外用药物和内服药物,内服药物以清热解毒、补益气血为主,外用药物以清热解毒、消肿止痛为主,二者同时使用在防治痔疮术后并发症方面具有预防效果好、起效快、安全性高、无毒副作用的优势。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物组份的医用配制品,特别涉及一种用于防治痔疮术后并发症的药物组合物及其制备方法。
背景技术
痔(俗称痔疮)是一种位于肛门部位的常见疾病,任何年龄都可发病,但随着年龄增长,发病率逐渐增高。在我国,痔是最常见的肛肠疾病,素有“十男九痔”、“十女十痔”的说法。痔疮是内痔、外痔、肛瘘、肛裂、脱肛、直肠息肉等各种肛门直肠疾病的总称,为肛肠科常见病、多发病,手术治疗仍是其重要手段之一。目前做痔疮手术是治疗痔疮最快的方法,可是手术毕竟是有危险的,如果不注意会出现并发症。由于手术时脉络受损、气血阻滞,气机运行不畅,而热毒内蕴,常常在手术后病发疼痛、出血、肛门缘水肿、肛门功能异常,创面不愈合等症状的出现,给病患的心身带来了一定的影响和恐惧。因此,如何简单、方便和有效地解除患者术后肛门疼痛、出血、水肿、坠涨等,促进创面愈合成为影响痔疮术后疗效的关键因素。
目前,虽然有一些用于治疗痔疮术后并发症的药物,如马应龙麝香痔疮膏等,但是疗效不明显,致使痔疮手术后并发症仍不能得到有效的防治。
发明内容
本发明所要解决的技术问题在于,提供一种用于防治痔疮术后并发症的药物组合物及其制备方法,该药物组合物以清热解毒、消肿止痛为主要治疗原则,防治痔疮术后并发症具有预防效果好、起效快、安全性高、无毒副作用和不易复发的优势。
为了解决上述技术问题,本发明提供了一种用于防治痔疮术后并发症的药物组合物,其中,包括外用药物和内服药物,所述外用药物包括以下原料药材:滑石、苦豆子、儿茶、金银花、千层塔、四叶草、白芍、五爪金龙、没药、蜂斗菜、粘人草和冰片;所述内服药物包括以下原料药材:野菊花、升麻、木贼、煅石膏、鸭跖草、黄柏、金银花、紫花地丁、金荞麦、大血藤、山慈菇、伸筋草、松节、青风藤、老鹤草、冬葵子、地耳草、延胡索、黄芪和夜交藤。
所述外用药物中各原料药材的重量份数为:滑石15-20重量份、苦豆子5-8重量份、儿茶5-11重量份、金银花15-25重量份、千层塔10-17重量份、四叶草8-12重量份、白芍10-18重量份、五爪金龙5-12重量份、没药5-18重量份、蜂斗菜9-18重量份、粘人草15-28重量份和冰片8-17重量份。
所述内服药物中各原料药材的重量份数为:所述内服药物中各原料药材的重量份数为:当归15-25重量份、野菊花15-20重量份、升麻10-18重量份、木贼15-20重量份、煅石膏5-10重量份、鸭跖草15-20重量份、黄柏15-25重量份、金银花15-25重量份、紫花地丁10-17重量份、金荞麦10-20重量份、大血藤8-15重量份、山慈菇8-12重量份、伸筋草15-20重量份、松节15-25重量份、青风藤10-20重量份、老鹤草12-18重量份、冬葵子11-17重量份、地耳草13-18重量份、延胡索15-20重量份、黄芪15-20重量份、大枣15-20重量份和夜交藤15-23重量份。
所述外用药物中各原料药材的重量份数优选为:滑石18重量份、苦豆子7重量份、儿茶7重量份、金银花21重量份、千层塔14重量份、四叶草10重量份、白芍14重量份、五爪金龙8重量份、没药11重量份、蜂斗菜14重量份、粘人草22重量份和冰片12重量份;
所述内服药物中各原料药材的重量份数优选为:所述内服药物中各原料药材的重量份数为:当归21重量份、野菊花17重量份、升麻14重量份、木贼18重量份、煅石膏7重量份、鸭跖草18重量份、黄柏19重量份、金银花21重量份、紫花地丁13重量份、金荞麦15重量份、大血藤12重量份、山慈菇10重量份、伸筋草18重量份、松节21重量份、青风藤15重量份、老鹤草15重量份、冬葵子14重量份、地耳草15重量份、延胡索17重量份、黄芪18重量份、大枣18重量份和夜交藤19重量份。
为了更好的实现上述发明目的,本发明还提供了一种用于防治痔疮术后并发症的药物组合物:
当外用药物的剂型为擦剂时,其制备方法包括以下步骤:先将除冰片外所述原料药材粉碎成粗粉,再进一步粉碎,过120目筛,使能通过120目筛的细粉量在达到30%,收集通过120目筛的细粉得细粉a;再将不能通过120目筛的粗粉投入多功能提取罐提取两次,第一次加8~10倍量水煎煮1~2小时,第二次加4~8倍量水煎煮1-2小时,合并两次煎液,过滤得滤液;加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉b,将细粉a与细粉b混合后备用,然后将冰片粉碎,加入细粉a与细粉b的混合物中,加0.1%~0.5%的氟化钠溶液制成擦剂。
当外用药物的剂型为膏剂时,其制备方法包括以下步骤:
步骤a、称取所述重量份数的苦豆子、千层塔、四叶草、五爪金龙和蜂斗菜混合,用混合物3~4倍量75~85%的乙醇浸泡1~2小时后,在70~80℃下热提取,加热浓缩乙醇提取液,浓缩至65℃时相对密度为1.08的浓缩液,静置备用;
步骤b、将除苦豆子、千层塔、四叶草、五爪金龙、蜂斗菜和冰片之外的其他所述原料药材按比例混合,投入粉碎机粉碎成细粉,细粉过筛后放入耐酸碱浸渍锅内,在常温常压下,与乙醇共同浸渍10~15天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液;
步骤c、将步骤a得到的浓缩液和步骤b得到的滤液混合,将所述冰片粉碎后混入上述混合物中,掺入凡士林或蜂蜡制成膏剂。
当内服药物的剂型为片剂时,其制备方法包括以下步骤:
第一步,将所述各原料药材按比例混合,加入相对于混合物质量2~4倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得300目~400目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.1~0.3倍的微晶纤维素、0.05~0.15倍乳糖、0.1~0.3倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.005~0.05倍硬脂酸镁,整粒,压片,制成。
当内服药物的剂型为口服液剂时,其制备方法包括以下步骤:
第一步,将野菊花、升麻和木贼混合,加相对于混合物3倍~5倍量醇浓度为55%~65%的乙醇回流提取2次~4次,每次2小时~3小时,过滤,滤液合并,回收乙醇,浓缩至70℃相对密度为1.30~1.32的膏体,备用;
第二步,将煅石膏、鸭跖草、黄柏、金银花、紫花地丁、金荞麦、大血藤、山慈菇、伸筋草、松节、青风藤、老鹤草、冬葵子、地耳草、延胡索、黄芪和夜交藤按比例混合,加相对于混合物3~5倍量水,煮沸2~4小时,过滤,浓缩至70℃相对密度为1.27~1.29的膏体;
第三步,将第一步、第二步获得的所述膏体混合,55℃~65℃减压真空干燥,得干膏粉;
第四步,将第三步获得的所述干膏粉中加入乙醇,得到含醇膏体,所述含醇膏体的含醇量为65%~70%;将所述含醇膏体依次进行冷藏处理、沉淀处理、过滤处理、回收乙醇处理,得到脱醇膏体,其中,冷藏处理时间为30~40小时;
第五步,将所述脱醇膏体中加入蔗糖粉、活性炭,依次进行加热处理、过滤处理、稀释处理,得到半成品;所述脱醇膏体与所述蔗糖粉的重量比为1∶0.1~0.3;所述脱醇膏体与所述活性炭的重量比为1∶0.001~0.002;所述加热处理的时间为20~40分钟,温度为100℃~110℃;
第六步,再将第五步获得的所述半成品依次进行过滤处理、灌封处理、灭菌处理,即得所述中药制剂口服液成品。
本发明的有益效果是:本发明药物组合物包括外用药物和内服药物,利用我国传统的中医理论,内服药物以清热解毒、补益气血为主要治疗原则,外用药物以清热解毒、消肿止痛为主要治疗原则,二者同时使用在防治痔疮术后并发症方面具有预防效果好、起效快、安全性高、无毒副作用和不易复发的优势。
具体实施方式
中医学在很早以前就采用外治法如《礼记》日:“头有疮则沐,身有疮则浴”。它是与内治法相对而言的,是使药物直接作用于皮肤或黏膜,使之快速吸收,而起到治疗作用的。痔疮术后的病机中,临床上以实证多见。痔疮病位在人体下部,故病因多为湿热毒邪为患,而各种病灶皆是脏腑功能紊乱,导致脾胃受伤,内生湿热,邪毒下注,积聚肛门所致,因此本发明在外用药物的基础上,配合使用以清热解毒、补益气血的外用药物;其中,外用药物包括以下原料药材:滑石、苦豆子、儿茶、金银花、千层塔、四叶草、白芍、五爪金龙、没药、蜂斗菜、粘人草和冰片,其中滑石解毒敛疮,苦豆子、金银花、四叶草、蜂斗菜清热解毒、利尿消肿,儿茶生肌敛疮,白芍、千层塔、粘人草、冰片消肿止痛,五爪金龙、没药散瘀消肿;内服药物包括以下原料药材:野菊花、升麻、木贼、煅石膏、鸭跖草、黄柏、金银花、紫花地丁、金荞麦、大血藤、山慈菇、伸筋草、松节、青风藤、老鹤草、冬葵子、地耳草、延胡索、黄芪和夜交藤,其中,野菊花、升麻、木贼、煅石膏、鸭跖草、黄柏、金银花清热解毒,紫花地丁、金荞麦、大血藤、山慈菇,利尿消肿;伸筋草、松节、青风藤、老鹤草、冬葵子、地耳草消肿止痛,延胡索消肿止痛;黄芪、夜交藤益气安神。
上述各原料药材的药理特性如下:
滑石:甘、淡,寒;归膀胱、肺、胃经。《本草经疏》:“滑石,滑以利诸窍,通壅滞,下垢腻。甘以和胃气,寒以散积热,甘寒滑利,以合其用,是为祛暑热,利水除湿,消积滞,利下窍之要药。”《本草衍义补遗》:“燥湿,分水道,实大肠,化食毒,行积滞,逐凝血,解燥渴,补脾胃,降心火之要药。”功用利尿通淋,清热解暑,祛湿敛疮。用于热淋,石淋,尿热涩痛,暑湿烦渴,湿热水泻;外治湿疹,湿疮,痱子。用于小便不利、淋沥涩痛等症,可配车前子、木通等品;用于湿热引起的水泻,可配合茯苓、薏苡仁、车前子等同用。对暑热病症可配合生甘草、鲜藿香、鲜佩兰等同用;治湿温胸闷、小便短赤,可配合生苡仁、通草,竹叶等同用。此外,本品外用还能清热收湿,用治湿疹、痱子等,可配石膏、炉甘石,枯矾等同用。滑石粉外用, 撒布于发炎或破损组织的表面时,可形成保护性膜.既可减少局部摩擦, 防止外来刺激,亦能吸收大量化学刺激物或毒物。
苦豆子:性味苦,寒,有毒。清热燥湿,止痛,杀虫。主治湿热泄痢,白带过多,溃疡等。从全草中提取的苦豆子总生物碱有抗炎、抗癌、抗变态反应、抗心率失常、抗溃疡、升高白细胞、平喘、解热、杀虫、镇静、镇痛、抗病毒等作用。苦豆子生物碱的药理作用:①对中枢神经系统的作用,体现在镇静催眠、镇痛及降温;②对心血管系统的作用,体现在抗心律失常、正性肌力作用,降压和降低心率作用,对心肌缺血和梗塞的保护作用,降血脂作用;③抗病毒、抗炎及免疫抑制作用,苦参总碱能抑制多种病毒繁殖.增强免疫调节功能和免疫促进作用;④抗肿瘤作用,对肝癌细胞抑制作用明显,对宫颈癌、淋巴肉瘤、肺癌也有抑制作用;⑤对平滑肌的作用,总碱和一些单体生物碱均能对抗由炎症介质诱导的离体回肠收缩,对支气管平滑肌具有松弛作用,对整体模型也有作用。
儿茶:味苦、涩,性微寒,归肺经,具有收湿生肌敛疮的功效,用于溃疡不敛,湿疹,口疮,跌扑伤痛,外伤出血等证。该品所含d-儿茶精及表儿茶精均有显著保肝作用。无抗原存在时d-儿茶精不影响白细胞游走,但体外试验抑制对纯化的蛋白衍生物(PPD)抗原敏感的正常人白细胞的游走,而对曾感染乙肝并对乙肝表面抗原敏感的患者其对白细胞游走的抑制作用更强,表明其能放大细胞介导的免疫反应而促进乙肝抗原的清除。儿茶水液灌服,可抑制空腹家兔十二指肠及小肠运动,促进盲肠逆蠕动,但对结肠无明显影响。
千层塔:辛;甘;微苦;平;温;凉;酸。归肺;大肠;肝;肾经;功能主治:清热解毒;燥湿敛疮;止血定痛散瘀;消肿。主肺炎;肺痈;劳伤吐血;痔疮便血;白带;跌打损伤;肿毒;水湿膨胀;溃疡久不收口;烫火伤。
四叶草:甘;苦;平。归肝;脾经。功能主治:清热;利尿;解毒;消肿。主尿路感染;癌肿;赤白带下;痢疾;痈肿;跌打损伤;咳血;妇女赤白带下;小儿疳积;痈肿疔毒;毒蛇咬伤。
白芍:苦、酸,微寒。归肝、脾经。功能主治:平肝止痛,养血调经,敛阴止汗。用于头痛眩晕,胁痛,腹痛,四肢挛痛,血虚萎黄,月经不调,自汗,盗汗。
五爪金龙:味辛;性温。功能主治:祛风除湿;接骨续筋;散瘀消肿。主风湿痹痛;跌打损伤骨折筋伤;水火烫伤;无名肿毒;皮肤湿烂
没药:苦,平。功能主治:散瘀止痛,外用消肿生肌。用于跌打淤血肿痛,痈疽肿痛,胸腹诸痛;外用治疮口久不收敛。
蜂斗菜:味苦;辛;性凉。功能主治:清热解毒;散瘀消肿。主咽喉肿痛;痈肿疔毒;毒蛇咬伤;跌打损伤
粘人草:甘、微辛,平。功能主治:消炎,杀菌,调经止痛。主治子宫脱垂,脱肛,腹痛,闭经,牛皮癣,神经性皮炎。
冰片: 辛、苦,微寒。归心、脾、肺经。功能主治:开窍醒神,清热止痛。用于热病神昏、痉厥,中风痰厥,气郁暴厥,中恶昏迷,目赤,口疮,咽喉肿痛,耳道流脓。
野菊花:性微寒,味苦、辛。《本草汇言》:“破血疏肝,解疔散毒。主妇人腹内宿血,解天行火毒丹疔。洗疮疥,又能去风杀虫。”功能清热解毒,消肿。对金黄色葡萄球菌、白喉杆菌、链球菌、绿脓杆菌、蒺疾杆菌、流感病毒,均有抑制作用。对疔疮,痈疽,丹毒,湿疹,皮炎,风热感冒,咽喉肿痛,高血压病等都有很好疗效。
升麻:味辛,甘,性微寒;归肺经、脾经、大肠经、胃经。《药性论》:“治小儿风,惊痫,时气热疾。能治口齿风NI肿疼,牙根浮烂恶臭,热毒脓血。除心肺风毒热壅闭不通,口疮,烦闷。疗痈肿,豌豆疮;水煎绵沾拭疮上。”《本草纲目》:“消斑疹,行瘀血,治阳陷眩运,胸胁虚痛,久泄下痢后重,遗浊,带下,崩中,血淋,下血,阴痿足寒。”功用清热解毒、透疹。用于麻疹透发不畅、热毒斑疹、外感表证,时疫火毒、口疮、咽痛、头痛寒热、痈肿疮毒、中气下陷、脾虚泄泻、久痢下重、妇女带下、崩中。
木贼:味甘、苦,性平;归肺、肝经。《本草纲目》:“木贼,与麻黄同形同性,故亦能发汗解肌,升散火郁风湿,治眼目诸血疾也。”《本草正义》:“发汗,解肌。治伤寒、疟疾。去风湿,散火邪。”木贼醇提物10-15g/kg腹腔注射或20g/kg十二指肠给药,对麻醉猫有持久的降压作用。降压强度和维持时间与剂量有一定的相关性。并能对抗组胺收缩血管作用,对切断脊髓的猫仍有降压作用,故认为其降压部位的外周性的。对家兔离体血管有明显扩张作用。木贼醇提取物低浓度时对家兔肠和豚鼠回肠有兴奋作用,能使肠肌收缩频率和肌张力增加,收缩振幅加大,高浓度时则呈抑制作用。木贼注射液对家兔呼吸和在位心脏无明显影响;对家兔离体心脏的收缩力有一定的抑制作用。
煅石膏:煅石膏为白色的粉末或酥松块状物,表面透出微红色的光泽,不透明。体较轻,质软,易碎,捏之成粉。无臭,味淡。甘、辛、涩,寒。归肺、胃经。收湿,生肌,敛疮,止血。外治溃疡不敛,湿疹瘙痒,水火烫伤,外伤出血。
鸭跖草:甘,寒,淡;入心,肝、脾、肾、大小肠诸经。《本草拾遗》:“主寒热瘴疟,痰饮,丁肿,肉症涩滞,小儿丹毒,发热狂痫,大腹痞满,身面气肿,热痢,蛇犬咬,痈疽等毒。”《滇南本草》:“补养气血,疗妇人白带、红崩,生新血,止尿血、鼻衄血、血淋。”用于外感发热,或热性病发热不退,或咽喉肿痛,以及痈肿疮疡等症。用于小便不利、水肿,或湿入下注膀胱、小便淋沥涩痛等症。同属植物茎叶的水浸剂或煎剂能兴奋子宫、收缩血管,并能缩短凝血时间。
黄柏:为芸香科植物黄皮树或黄檗的干燥树皮。前者习称“川黄柏”,后者习称“关黄柏”。可入药,性味苦寒,有清热燥湿,泻火除蒸,解毒疗疮之功效。黄檗分布于中国东北和华北各省等地区,喜生长于山区、杂林之中,适应性强,适合阳光充足的地方栽培,也能抗严寒。黄柏为常用中药,其性寒、味苦,具清热燥湿、泻火解毒等功效,常用于湿热泻痢、黄疸、白带以及热痹、热淋等症。现代研究表明,黄柏含小蘖碱、黄柏酮等主要成分,有抗菌、收敛、消炎的作用,对各种皮肤湿毒、疮疡等症状,功效良好。《本经逢原》曰:“黄柏,生用降实火,酒制治阴火上炎,盐制治下焦之火,姜制治中焦痰火,姜汁炒黑治湿热,盐酒炒黑制虚火,阴虚火盛面赤戴阳,附子汁制”。
金银花:性寒,味甘,入肺、心、胃经,具有清热解毒、抗炎、补虚疗风的功效,主治胀满下疾、温病发热,热毒痈疡和肿瘤等症。其对于头昏头晕、口干作渴、多汗烦闷、肠炎、菌痢、麻疹、肺炎、乙脑、流脑、急性乳腺炎、败血症、阑尾炎、皮肤感染、痈疽疔疮、丹毒、腮腺炎、化脓性扁桃体炎等病症均有一定疗效。同时金银花茶有独特的减肥功能,还能抑制与杀灭咽喉部的病原菌,对老人和儿童有抗感染功效。所以,经常服用金银花浸泡或煎剂有利于风火目赤、咽喉肿痛、肥胖症、肝热症和肝热型高血压的治疗与康复。温病初期:常与;连翘、薄荷、淡豆鼓等同用,具有清热解毒、疏风解表作用,可用以温病初期,发热微恶寒风寒,口微渴,如银翘散。痈疽疔毒:常与蒲公英、紫地丁、野菊花等同用,能增强清热解毒作用,可用以痈疽疔毒,红肿疼痛,如五味消毒饮。金银花有较好的退热作用,能抗炎,控制炎症的渗出和炎性增生,能促进白细胞的吞噬功能,对多种化脓性球菌及肠道致病菌有较强的抑菌作用,包括葡萄球菌、溶血性链球菌、脑膜炎双球菌、痢疾杆菌、伤寒杆菌、新城疫、绿脓杆菌、结核杆菌等。此外金银花还有利胆保肝、抗氧化、降血脂、中枢兴奋等作用。
紫花地丁:味苦、辛,性寒,入心、肝经,具有清热解毒、凉血消肿的作用,主流行性感冒;上呼吸道感染;扁桃体炎;传染性肝炎;肠炎;痢疾;肾炎;腮腺炎;结膜炎;急性阑尾炎;疔疮痈肿;瘰疬。清热解毒。治疔疮痈肿,黄疸内热,小儿鼻血,阑尾炎,毒蛇咬伤。①《滇南本草》:破血,解痈疽疥癞,九种痔疮,诸疮毒症。②《纲目》:主治一切痈疽发背,疔肿瘰疬,无名肿毒,恶疮。③《本草求原》:凉血,消肿毒。治血热筋痿,敷疮妙。④《岭南采药录》:作泻药及吐药。⑤《上海常用中草药》:清热解毒,外用拔毒消肿。治目赤肿痛,麦粒肿,疗疮肿毒,乳痈,肠炎腹泻,毒蛇咬伤。⑥苏医《中草药手册》:治一切化脓性感染,毒蛇咬伤,淋巴结核,黄疸,肾炎,膀胱炎,关节肿痛,便血,鼻出血,眼结膜炎,前列腺炎。紫花地丁对黄金色葡萄球菌、肺炎杆菌、大肠杆菌、甲型链球菌、乙型链球菌、流感杆菌、白喉杆菌、绿脓杆菌、白色葡萄糖球菌、白色念珠菌有不同程度的抑制作用。
金荞麦:性凉,味辛、苦。能清热解毒,活血消痈,祛风除湿疮毒,蛇虫咬伤。主肺痈,肺热咳喘,咽喉肿痛,痢疾,风湿痹证,跌打损伤,痈肿癌。用作清热解毒,据江苏南通经验,必须隔水炖汁服,煎服则疗效不显著。临床用治咽喉肿痛,常配伍灯笼草、筋骨草等同用;用治肺热咳嗽,或肺痈,可单用本品一两,隔水炖汁服,也可配合鱼腥草等药同用。治疗手足关节不利,风湿筋骨酸痛等症,常配合桑枝、络石藤、苍术等药同用。体外实验虽无明显抗菌作用,但对金黄色葡萄球菌的凝固酶、溶血素及绿脓杆菌内毒素有对抗作用。
大血藤:味苦,性平,归肝、大肠经,《湖南药物志》:“通经补血,强筋壮骨,驱虫。治跌打损伤,风湿疼痛,血晕,血淋,筋骨疼痛,疮疖,血丝虫病。”《简易草药》:“治筋骨疼痛,追风,健腰膝,壮阳事。”具有败毒消痈,活血通络,祛风杀虫的作用,主治急、慢性阑尾炎,风湿痹痛,赤痢,血淋,月经不调,疳积,虫痛,跌扑损伤等证。对离体蟾蜍心脏的作用按八木氏离体心脏装置,以20ml任氏液灌流,将0.1g红藤加入灌流液中(0.5%),发现对离体心脏呈轻度抑制,表现心缩力减弱,心率减慢(P0.05),心输出量减少(P0.01)。对离体家兔主动脉条的作用将离体家兔的主动脉条,结果血管开始出现明显的收缩作用,该作用可被酚妥拉明阻断,提示其收缩作用可能与a-受体有关。随后又渐出现持久的松弛作用。
山慈菇:苦、微辛、凉。消肿散结,化痰,清热解毒。治痈疽疖肿,咽喉肿痛,喉痹,瘰疬。《本草拾遗》:“主痈肿疮瘘,瘰疬结核等,醋磨敷之。”《本草纲目》:“主疔肿,攻毒破皮。解诸毒,蛇虫、狂犬伤。”对乳痈肿、痈肿疔毒、瘰历结核,内服、外敷,均可应用。
伸筋草:苦、辛、温,入肝经。《本草拾遗》:“主人久患风痹,脚膝疼冷,皮肤不仁,气力衰弱。”《湖南药物志》:“舒筋活血,补气通络。治腰痛,关节痛,闭经。”祛风散寒,除湿消肿,舒筋活络。用于风寒湿痹,筋脉拘挛疼痈。外用治跌打扭伤肿痛。本品水浸剂对实验家兔有降温作用。30毫克/公斤静脉注射石松碱可使麻醉猫、兔血压骤降,中毒剂量可增加动物呼吸振幅而减少频率。体外对福氏痢疾杆菌、宋内氏痢疾杆菌高度敏感,对志贺氏痢疾杆菌中度敏感。石松碱对蛙心收缩力有增强作用。对离体大鼠、豚鼠、家兔小肠平滑肌有兴奋作用。对兔、大鼠及豚鼠子宫有兴奋作用。
松节:苦,温;入心经、肺经。《滇南本草》:"行经络,治痰火,筋骨疼痛,湿痹痿软,强筋骨。"《日华子本草》:"治脚软骨节风。"《本草汇言》:“松节,气温性燥,如足膝筋骨,有风有湿,作痛作酸,痿弱无力者,用此立痊。倘阴虚髓乏,血燥有火者,宜斟酌用之。”功用祛风燥湿,止痛。主治风寒湿痹,历节风痛,脚痹痿软,跌打伤痛。松节有一定的镇痛、抗炎作用;提取的酸性多糖显示抗肿瘤作用;提取的多糖类物质、热水提取物、酸性提取物都具有免疫活性。
青风藤:苦、辛;归肝、脾经。《本草纲目》:“治风湿流注,历节鹤膝,麻痹瘙痒,损伤疮肿,入酒药中用。”《浙江天目山药植志》:“行水利尿,泻下焦血分湿热。治风水肿,脚气,风湿关节疼痛,口眼歪斜,痈肿恶疮。”功能祛风湿,通经络,利小便。用于风湿痹痛,关节肿胀,麻痹瘙痒。清风藤散风寒湿痹,能舒筋活血,正骨利髓,故风病软弱无力,并劲强偏废之证,久服常服,大建奇功。须与当归、枸杞合用方善也。青藤碱在用小鼠电刺激法、热板法以及家兔光热刺激法的试验中,均证明具有肯定的镇痛作用。青藤总碱对麻醉或不麻醉实验动物(犬、猫、兔、大鼠),无论静脉注射或灌胃都有肯定的急性降压效果。
老鹤草:苦、微辛,平。归肝、肾、大肠经。《滇南本草》:“治子午潮热,眩晕,怕冷,肢体酸困,饮食无味,男老鹤草妇童疳,虚劳发热不退者用之,利小便,水牛肉为引。”祛除风湿,用于风湿痹痛。老鹤草野老鹤草根的提取物含有类黄酮、儿茶素、单宁,能抑制多种病毒的复制(如流感、单纯疱疹、牛痘、HIV-I)其中抗流感病毒的作用最明显。老鹤草能抑制肝脏线粒体和微粒体的脂质过氧化,降低血浆胆固醇及GOT/GPT水平,抑制由ADP和抗坏 血酸诱发的线粒体脂质过氧化作用。老鹤草提取物的灭菌水溶液在体外对福氏痢疾杆菌、大肠杆菌、金黄葡萄球菌、绿脓杆菌均有抑制作用。
冬葵子:甘,寒;入大小肠、膀胱经。行水滑肠,通乳,清热排脓。治二便不通,淋病,水肿,妇女乳汁不行,乳房肿痛。配冬瓜子,利湿止痛,滑利排脓作用增强;配砂冬葵子仁,行气下乳;配茯苓,健脾利水;配王不留行,通乳作用增强;配火麻仁,润燥,滑肠,通便;配木通,用于产后因热乳汁不通,津液亏损之便秘,热淋涩痛,心火上炎,口舌生疮,心烦尿赤。种子含脂肪油及蛋白质。花含花青素类。鲜冬葵含单糖6.8~7.4%,蔗糖4.1~4.6 %,麦芽糖4.5~4.8%,淀粉1.2%。种子含15%~20%,其中亚油酸为主;叶含芸香甙,根含粘液质,其中有戊糖、戊聚糖、甲基戊聚糖、糖醛酸和微量甲基戊糖。脾虚肠滑者忌服,孕妇慎服。
地耳草:味苦、平;归肝、胆经。《生草药性备要》:“治酒病,消肿胀,敷大恶疮,理疳疮肿。”《岭南采药录》:"去硝黄火毒,敷虾箝疮,理跌打、蛇伤。"利湿退黄,清热解毒,活血消肿。治传染性肝炎,泻痢,小儿惊风,疳积,喉蛾,肠痈,疖肿,蛇咬伤。本品苦凉,入肝胆经,能清肝胆湿热有利胆退黄作用,单用大剂量煎服或与金钱草、茵陈蒿、虎杖等配伍。对急性黄疸型肝炎、慢性肝炎均有治疗作用。本品活血消肿,用于跌打损伤瘀肿疼痛,单用或配骨碎补、乳香、没药等煎服;亦可同时用鲜品捣烂外敷。在试管内对牛型结核杆菌、肺炎球菌、金黄色葡萄球菌、猪霍乱杆菌和痢疾杆菌有不同程度的抑菌和杀菌作用。
延胡索:活血,散瘀,理气,止痛。主心腹腰膝诸痛,月经不调,症瘕,崩中,产后血晕,恶露不尽,跌打损伤。用于胸胁、脘腹疼痛,经闭痛经,产后瘀阻,跌扑肿痛。1、镇痛作用:延胡索粉有镇痛作用,其止痛效价约为阿片的1/100;延胡索总碱、延胡索甲素、乙素、丑素、癸素均有镇痛作用,以乙素较强.各种剂型以醇制浸膏及粉剂作用强。2、镇静、安定、催眠作用:延胡索乙素具有一定的镇静、安定作用,其左旋体为新型的中枢抑制剂,较大剂量时对兔、狗、猴有明显的催眠作用。3、对消化系统的影响:去氢延胡索甲素有显著的抗大鼠实验性胃溃疡作用。4、对心血管的作用:延胡索乙素、丑素有轻微降压、减慢心率作用;去氢延胡索碱有降压、增加冠状窦血流量作用。醇提物也有扩张冠脉、对抗异丙肾上腺素引起的大鼠心肌坏死作用。
黄芪:甘,微温;归肺、脾、肝、肾经。《本草备要》:“黄芪,生用固表,无汗能发,有汗能止;炙用补中,益元气,壮脾胃。生血,生肌,排脓内托,疮痈圣药。痘症不起,阳虚无热者宜之。”《本草正义》:“黄芪,补益中土,温养脾胃,凡中气不振,脾土虚弱,清气下陷者最宜。其皮直达人之肤表肌肉,固护卫阳,充实表分,是其专长,所以表虚诸病,最为神剂。”功用固表敛汗,利水消肿,托疮排脓,通调水道。黄芪使心脏收缩能力增强,能改善全身的血液循环,能扩张冠状动脉、肾血管及拳参末梢血管、使皮肤血液循环旺盛;能提高机体的非特异免疫力,有保肝和降低血糖的作用,对葡萄球菌、血溶性链球菌、肺炎双球菌、痢疾杆菌等有抑制作用。黄芪可显著影响脾淋巴细胞信息传导,实现免疫调节作用。可用于高血压病,缺血性心脏病,急性肾小球肾炎,胃溃疡,银屑病,糖尿病,骨质疏松。
夜交藤:甘微苦,平。养心,安神,通络,祛风,治失眠症,劳伤,多汗,血虚身痛,痈疽,瘰疬,风疮疥癣。夜交藤具有养血安神作用,以用于阴虚血少所致的失眠为主,常与合欢皮相须配合,也可与枣仁、柏子仁、远志等同用。夜交藤既有养血作用,还可通利经络,治血虚周身酸痛,可配合当归、地黄、鸡血藤、络石藤等同用。夜交藤煎汤外洗治皮肤痒疹,有一定止痒作用。有人将夜交藤添加到粮食中,试制成含有夜交藤成分的保健食品,其功效、作用可与何首乌食品相媲美,长期食用,能养心安神、通络祛风,畅大便、助消化,对人体有益无害,这显示了夜交藤更宽广的应用前景。
以下采用实施例来详细说明本发明的实施方式,借此对本发明如何应用技术手段来解决技术问题,并达成技术效果的实现过程能充分理解并据以实施。
实施例1 擦剂
本发明实施例提供了一种用于防治痔疮术后并发症的外用药物,由以下重量份数的原料药材制成:滑石15重量份、苦豆子5重量份、儿茶5重量份、金银花25重量份、千层塔17重量份、四叶草12重量份、白芍10重量份、五爪金龙12重量份、没药5重量份、蜂斗菜18重量份、粘人草28重量份和冰片8重量份;
其制备方法包括以下步骤:
先将除冰片外所述原料药材粉碎成粗粉,再进一步粉碎,过120目筛,使能通过120目筛的细粉量在达到30%,收集通过120目筛的细粉得细粉a;再将不能通过120目筛的粗粉投入多功能提取罐提取两次,第一次加9倍量水煎煮1.5小时,第二次加6倍量水煎煮1.5小时,合并两次煎液,过滤得滤液;加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉b,将细粉a与细粉b混合后备用,然后将冰片粉碎,加入细粉a与细粉b的混合物中,加0.3%的氟化钠溶液制成擦剂。
实施例2 膏剂
本发明实施例提供了一种用于防治痔疮术后并发症的外用药物,由以下重量份数的原料药材制成:滑石18重量份、苦豆子7重量份、儿茶7重量份、金银花21重量份、千层塔14重量份、四叶草10重量份、白芍14重量份、五爪金龙8重量份、没药11重量份、蜂斗菜14重量份、粘人草22重量份和冰片12重量份;
其制备方法包括以下步骤:
步骤a、称取所述重量份数的苦豆子、千层塔、四叶草、五爪金龙和蜂斗菜混合,用混合物3倍量80%的乙醇浸泡1.5小时后,在75℃下热提取,加热浓缩乙醇提取液,浓缩至65℃时相对密度为1.08的浓缩液,静置备用;
步骤b、将除苦豆子、千层塔、四叶草、五爪金龙、蜂斗菜和冰片之外的其他所述原料药材按比例混合,投入粉碎机粉碎成细粉,细粉过筛后放入耐酸碱浸渍锅内,在常温常压下,与乙醇共同浸渍12天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液;
步骤c、将步骤a得到的浓缩液和步骤b得到的滤液混合,将所述冰片粉碎后混入上述混合物中,掺入凡士林或蜂蜡制成膏剂。
实施例3 片剂
本发明实施例提供了一种用于防治痔疮术后并发症的内服药物,由以下重量份数的原料药材制成:当归15重量份、野菊花20重量份、升麻10重量份、木贼20重量份、煅石膏5重量份、鸭跖草15重量份、黄柏25重量份、金银花15重量份、紫花地丁10重量份、金荞麦20重量份、大血藤8重量份、山慈菇8重量份、伸筋草15重量份、松节15重量份、青风藤20重量份、老鹤草18重量份、冬葵子11重量份、地耳草13重量份、延胡索15重量份、黄芪20重量份、大枣15重量份和夜交藤15重量份;
其制备方法包括以下步骤:
第一步,将所述各原料药材按比例混合,加入相对于混合物质量3倍的醇浓度为90%的乙醇,加热回流2小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1.5倍的醇浓度为90%的乙醇,加热回流2小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1.5小时,粉碎,过筛,获得350目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.2倍的微晶纤维素、0.1倍乳糖、0.2倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.025倍硬脂酸镁,整粒,压片,制成。
实施例4 口服液剂
本发明实施例提供了一种用于防治痔疮术后并发症的内服药物,由以下重量份数的原料药材制成:当归21重量份、野菊花17重量份、升麻14重量份、木贼18重量份、煅石膏7重量份、鸭跖草18重量份、黄柏19重量份、金银花21重量份、紫花地丁13重量份、金荞麦15重量份、大血藤12重量份、山慈菇10重量份、伸筋草18重量份、松节21重量份、青风藤15重量份、老鹤草15重量份、冬葵子14重量份、地耳草15重量份、延胡索17重量份、黄芪18重量份、大枣18重量份和夜交藤19重量份;
其制备方法包括以下步骤:
第一步,将野菊花、升麻和木贼混合,加相对于混合物4倍量醇浓度为60%的乙醇回流提取3次,每次2.5小时,过滤,滤液合并,回收乙醇,浓缩至70℃相对密度为1.31的膏体,备用;
第二步,将煅石膏、鸭跖草、黄柏、金银花、紫花地丁、金荞麦、大血藤、山慈菇、伸筋草、松节、青风藤、老鹤草、冬葵子、地耳草、延胡索、黄芪和夜交藤按比例混合,加相对于混合物4倍量水,煮沸3小时,过滤,浓缩至70℃相对密度为1.28的膏体;
第三步,将第一步、第二步获得的所述膏体混合,60℃减压真空干燥,得干膏粉;
第四步,将第三步获得的所述干膏粉中加入乙醇,得到含醇膏体,所述含醇膏体的含醇量为68%;将所述含醇膏体依次进行冷藏处理、沉淀处理、过滤处理、回收乙醇处理,得到脱醇膏体,其中,冷藏处理时间为35小时;
第五步,将所述脱醇膏体中加入蔗糖粉、活性炭,依次进行加热处理、过滤处理、稀释处理,得到半成品;所述脱醇膏体与所述蔗糖粉的重量比为1∶0.2;所述脱醇膏体与所述活性炭的重量比为1∶0.001;所述加热处理的时间为30分钟,温度为105℃;
第六步,再将第五步获得的所述半成品依次进行过滤处理、灌封处理、灭菌处理,即得所述中药制剂口服液成品。
毒性试验
试验一:本发明急性毒性试验
试验材料:动物:昆明种小鼠,体重21-24g,雌雄各半;药物:本发明片剂。
方法:1、LD50计算:采用改良寇氏法,将小鼠随机分成5组,每组10只,雌雄各半,将片剂加蒸馏水溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。2、最大耐受剂量测定(MTD值):取小鼠20只,雌雄各10只。将片剂加蒸馏水溶解,配成最高浓度,按动物的最大耐受量,以注射灌喂器能抽动为准。在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml(每ml含生药0.36g),总药量为18g生药/kg.d,相当临床成人 50Kg体重用量的300倍。给药后连续观察7天。
试验结果:在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时 (18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,在7天观察期中,动物其食欲、活动、毛色、精神状态等皆正常,发育正常,未见有死亡。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
实验二:长期毒性实验
实验方法:选取健康豚鼠45只,将豚鼠随机份成3组,每组15只。在豚鼠背部脊柱两侧将脱毛剂均匀涂上,使其脱毛范围约40平方厘米。洗净脱毛剂,观察24小时后每组豚鼠分别涂本发明膏剂0.2、0.4和0.8ml,分别含生药92、184和368mg,另一组涂溶媒0.8ml每日二次,连续30天,观察豚鼠的一般情况,实验结束后处死动物进行血液学、血液生化及病理学检查。
结果:上述三组用药豚鼠躯干去毛区,未见局部皮肤有水肿、充血、红斑、出血点及溃疡。用药组与对照组动物毛发色泽、摄食、四肢活动等对照组无明显差异,血液生化检查,用药组与对照组均在正常范围。病理组织学检查,实验各组心、肝、肾及局部皮肤均未见明显病变。提示,本发明中药制剂长期用药对局部皮肤及全身重要脏器均未见明显的毒性作用。试验结果表明:本发明中药制剂实验安全。该药对乙型链球菌、金黄色葡萄球菌、大肠杆菌的最小抑制浓度为1∶150,淋球菌为1∶150,白色念珠菌为1∶300,对阴道老年1∶20稀释度时的杀灭时间为5分钟,1∶50时为10分钟,1∶100时为20分钟,1∶200时为40 分钟,1∶400时为8小时。
实验三:累计毒性实验
本发明中药制剂内服口服液剂对小鼠按7.69、19.18和43.21g生药/kg连续用药15周(1.0ml/100g体重,每天2次)及停药3周后,结果表明:本发明中药制剂对大鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药15周及停药3周后,大鼠各脏器均无明显改变。说明本发明中药制剂内服口服液剂对大鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
实验四:皮肤刺激性试验
取家兔剃毛,对该外用药物擦剂进行诱导和激发接触试验,在24小时和48小时后观察试验家兔,均不见皮肤有红斑及水肿等现象,与阴性对照组无差异。结果表明,该制剂对皮肤反应强度近于零,即无皮肤变态反应。对白鼠阴道和破损皮肤进行刺激性试验,未见有刺激性反应和其它不良。对滤过性病毒有抑制和杀灭作用反应。毒性试验证明,该药未有毒性作用和不良反应,临床应用安全可靠。
临床试验
2011年7月-2013年4月前来本院就诊的痔疮患者300例,年龄28-63岁,平均年龄42.1岁,男158例,女142例,其中,混合痔201例,内痔肿物外脱75例,外痔肿大疼痛难忍24例,上述患者均需进行痔疮手术,将上述300例患者随机分成三组,分别为结合治疗组1、结合治疗组2和对照组,每组100例,各组患者在年龄、病情、手术等情况无统计学意义,具有可比性。
防治方法:(术后第二天开始每日排便后进行如下治疗)
结合治疗组1:使用本发明实施例2的膏剂和实施例4的口服液共同治疗,膏剂每日涂抹患处,每日1-2次,口服液每日两次,每次20ml,连用7-14天;
结合治疗组2:使用本发明实施例1的擦剂和实施例3的片剂共同治疗,擦剂每日2-3次,片剂每日两次,每次3片,连用7-14天;
对照组:使用马应龙麝香痔疮膏涂患处,每日1-2次,连用7-14天。
疗效标准:
治愈:症状及体征消失,创面愈合,用药后肛门缘水肿、疼痛消失;显效:症状及体征明显改善,创面未完全愈合,用药后肛门缘水肿、疼痛等程度明显减轻;有效:症状及体征有所改善,用药后肛门水肿、疼痛等成都有所减轻;无效:症状及体征无变化,用药后肛门缘水肿、疼痛等程度无减轻,甚至加重;其中,有效率为治愈数和显效数之和占总数的百分比。
治疗结果:
参见表1和表2,从表1可以看出,采用本发明的药物组合物防治痔疮术后并发症,相对于传统药物在治疗效果上,具有显著的改进;从表2可以看出,采用本发明的药物组合物防治痔疮术后并发症,相对于传统药物,在治疗疗程上显著缩短。
表1三组分别治疗7-14天后临床疗效比较 例
| 组别 | 总数 | 治愈 | 显效 | 有效 | 无效 | 有效率 |
| 结合治疗组1 | 100 | 74 | 22 | 4 | 0 | 96% |
| 结合治疗组2 | 100 | 69 | 26 | 5 | 0 | 95% |
| 对照组 | 100 | 56 | 24 | 16 | 4 | 80% |
表2三组分别治疗7-14天后治愈和显效人数和时间比较 例(%)
| 组别 | 总数 | 第1-5天 | 第6-10天 | 第11-14天 |
| 结合治疗组1 | 96 | 39(40.6%) | 41(42.7%) | 16(16.7%) |
| 结合治疗组2 | 95 | 35(36.8%) | 43(45.3%) | 17(17.9%) |
| 对照组 | 80 | 18(22.5%) | 29(36.3%) | 33(41.3%) |
根据上述表格内的临床统计可知,本发明提供的药物组合物具有起效快、有效率高、疗效确切、安全性高、无毒副作用的优势。
典型病例
孙某,男,51岁,前来就诊时经检查内痔肿物外脱,大便后肿物外脱,经诊断需进行手术,术后第二天开始每日排便后,使用本发明实施例2的膏剂和实施例4的口服液共同治疗,膏剂每日涂抹患处,每日2次,口服液每日两次,每次20ml,连用3天,创面愈合较快,肛门缘水肿、疼痛等程度明显减轻,继续服用3天痊愈。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.用于防治痔疮术后并发症的药物组合物,其特征在于,所述药物组合物包括外用药物和内服药物,所述外用药物包括以下原料药材:滑石、苦豆子、儿茶、金银花、千层塔、四叶草、白芍、五爪金龙、没药、蜂斗菜、粘人草和冰片;所述内服药物包括以下原料药材:野菊花、升麻、木贼、煅石膏、鸭跖草、黄柏、金银花、紫花地丁、金荞麦、大血藤、山慈菇、伸筋草、松节、青风藤、老鹤草、冬葵子、地耳草、延胡索、黄芪和夜交藤。
2.根据权利要求1所述的用于防治痔疮术后并发症的药物组合物,其特征在于,所述外用药物中各原料药材的重量份数为:滑石15-20重量份、苦豆子5-8重量份、儿茶5-11重量份、金银花15-25重量份、千层塔10-17重量份、四叶草8-12重量份、白芍10-18重量份、五爪金龙5-12重量份、没药5-18重量份、蜂斗菜9-18重量份、粘人草15-28重量份和冰片8-17重量份。
3.根据权利要求1或2所述的用于防治痔疮术后并发症的药物组合物,其特征在于,所述内服药物中各原料药材的重量份数为:所述内服药物中各原料药材的重量份数为:当归15-25重量份、野菊花15-20重量份、升麻10-18重量份、木贼15-20重量份、煅石膏5-10重量份、鸭跖草15-20重量份、黄柏15-25重量份、金银花15-25重量份、紫花地丁10-17重量份、金荞麦10-20重量份、大血藤8-15重量份、山慈菇8-12重量份、伸筋草15-20重量份、松节15-25重量份、青风藤10-20重量份、老鹤草12-18重量份、冬葵子11-17重量份、地耳草13-18重量份、延胡索15-20重量份、黄芪15-20重量份、大枣15-20重量份和夜交藤15-23重量份。
4.根据权利要求1-3任一项所述的用于防治痔疮术后并发症的药物组合物,其特征在于,所述外用药物中各原料药材的重量份数为:滑石18重量份、苦豆子7重量份、儿茶7重量份、金银花21重量份、千层塔14重量份、四叶草10重量份、白芍14重量份、五爪金龙8重量份、没药11重量份、蜂斗菜14重量份、粘人草22重量份和冰片12重量份。
5.根据权利要求1-4任一项所述的用于防治痔疮术后并发症的药物组合物,其特征在于,所述内服药物中各原料药材的重量份数为:所述内服药物中各原料药材的重量份数为:当归21重量份、野菊花17重量份、升麻14重量份、木贼18重量份、煅石膏7重量份、鸭跖草18重量份、黄柏19重量份、金银花21重量份、紫花地丁13重量份、金荞麦15重量份、大血藤12重量份、山慈菇10重量份、伸筋草18重量份、松节21重量份、青风藤15重量份、老鹤草15重量份、冬葵子14重量份、地耳草15重量份、延胡索17重量份、黄芪18重量份、大枣18重量份和夜交藤19重量份。
6.根据权利要求1-5任一项所述的用于防治痔疮术后并发症的药物组合物,其特征在于,所述外用药物的剂型为擦剂,其制备方法包括以下步骤:先将除冰片外所述原料药材粉碎成粗粉,再进一步粉碎,过120目筛,使能通过120目筛的细粉量在达到30%,收集通过120目筛的细粉得细粉a;再将不能通过120目筛的粗粉投入多功能提取罐提取两次,第一次加8~10倍量水煎煮1~2小时,第二次加4~8倍量水煎煮1-2小时,合并两次煎液,过滤得滤液;加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉b,将细粉a与细粉b混合后备用,然后将冰片粉碎,加入细粉a与细粉b的混合物中,加0.1%~0.5%的氟化钠溶液制成擦剂。
7.根据权利要求1-5任一项所述的用于防治痔疮术后并发症的药物组合物,其特征在于,所述外用药物的剂型为膏剂,其制备方法包括以下步骤:
步骤a、称取所述重量份数的苦豆子、千层塔、四叶草、五爪金龙和蜂斗菜混合,用混合物3~4倍量75~85%的乙醇浸泡1~2小时后,在70~80℃下热提取,加热浓缩乙醇提取液,浓缩至65℃时相对密度为1.08的浓缩液,静置备用;
步骤b、将除苦豆子、千层塔、四叶草、五爪金龙、蜂斗菜和冰片之外的其他所述原料药材按比例混合,投入粉碎机粉碎成细粉,细粉过筛后放入耐酸碱浸渍锅内,在常温常压下,与乙醇共同浸渍10~15天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液;
步骤c、将步骤a得到的浓缩液和步骤b得到的滤液混合,将所述冰片粉碎后混入上述混合物中,掺入凡士林或蜂蜡制成膏剂。
8.根据权利要求1-5任一项所述的用于防治痔疮术后并发症的药物组合物,其特征在于,所述内服药物的剂型为片剂,其制备方法包括以下步骤:
第一步,将所述各原料药材按比例混合,加入相对于混合物质量2~4倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得300目~400目的超微细粉;
第三步,将第二步获得的超微细粉,加入相对于其质量0.1~0.3倍的微晶纤维素、0.05~0.15倍乳糖、0.1~0.3倍的淀粉,过筛,混合均匀,制粒,干燥,加入相对于超微细粉质量0.005~0.05倍硬脂酸镁,整粒,压片,制成。
9.根据权利要求1-5任一项所述的用于防治痔疮术后并发症的药物组合物,其特征在于,所述内服药物的剂型为口服液剂,其制备方法包括以下步骤:
第一步,将野菊花、升麻和木贼混合,加相对于混合物3倍~5倍量醇浓度为55%~65%的乙醇回流提取2次~4次,每次2小时~3小时,过滤,滤液合并,回收乙醇,浓缩至70℃相对密度为1.30~1.32的膏体,备用;
第二步,将煅石膏、鸭跖草、黄柏、金银花、紫花地丁、金荞麦、大血藤、山慈菇、伸筋草、松节、青风藤、老鹤草、冬葵子、地耳草、延胡索、黄芪和夜交藤按比例混合,加相对于混合物3~5倍量水,煮沸2~4小时,过滤,浓缩至70℃相对密度为1.27~1.29的膏体;
第三步,将第一步、第二步获得的所述膏体混合,55℃~65℃减压真空干燥,得干膏粉;
第四步,将第三步获得的所述干膏粉中加入乙醇,得到含醇膏体,所述含醇膏体的含醇量为65%~70%;将所述含醇膏体依次进行冷藏处理、沉淀处理、过滤处理、回收乙醇处理,得到脱醇膏体,其中,冷藏处理时间为30~40小时;
第五步,将所述脱醇膏体中加入蔗糖粉、活性炭,依次进行加热处理、过滤处理、稀释处理,得到半成品;所述脱醇膏体与所述蔗糖粉的重量比为1∶0.1~0.3;所述脱醇膏体与所述活性炭的重量比为1∶0.001~0.002;所述加热处理的时间为20~40分钟,温度为100℃~110℃;
第六步,再将第五步获得的所述半成品依次进行过滤处理、灌封处理、灭菌处理,即得所述中药制剂口服液成品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410403174.2A CN104127737A (zh) | 2014-08-18 | 2014-08-18 | 用于防治痔疮术后并发症的药物组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410403174.2A CN104127737A (zh) | 2014-08-18 | 2014-08-18 | 用于防治痔疮术后并发症的药物组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104127737A true CN104127737A (zh) | 2014-11-05 |
Family
ID=51800759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410403174.2A Pending CN104127737A (zh) | 2014-08-18 | 2014-08-18 | 用于防治痔疮术后并发症的药物组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104127737A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105106749A (zh) * | 2015-09-02 | 2015-12-02 | 江淑芬 | 一种普外科治疗痔疮的中药组合物 |
| CN105169018A (zh) * | 2015-09-02 | 2015-12-23 | 江淑芬 | 一种普外科治疗痔疮的中药组合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612252A (zh) * | 2009-07-16 | 2009-12-30 | 邓泽潭 | 一种治疗痔疮术后并发症的中药外洗冲剂 |
| CN102670751A (zh) * | 2012-06-05 | 2012-09-19 | 上海中医药大学附属岳阳中西医结合医院 | 一种缓解混合痔外剥内扎术后并发症的中药组合物 |
| CN103599263A (zh) * | 2013-12-10 | 2014-02-26 | 王小欧 | 一种用于痔疮的中药及其制备方法 |
-
2014
- 2014-08-18 CN CN201410403174.2A patent/CN104127737A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612252A (zh) * | 2009-07-16 | 2009-12-30 | 邓泽潭 | 一种治疗痔疮术后并发症的中药外洗冲剂 |
| CN102670751A (zh) * | 2012-06-05 | 2012-09-19 | 上海中医药大学附属岳阳中西医结合医院 | 一种缓解混合痔外剥内扎术后并发症的中药组合物 |
| CN103599263A (zh) * | 2013-12-10 | 2014-02-26 | 王小欧 | 一种用于痔疮的中药及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 张利新等: "痔术后并发症防治研究的进展", 《贵州省中西医结合学会肛肠学会第三届学术交流会论文汇编》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105106749A (zh) * | 2015-09-02 | 2015-12-02 | 江淑芬 | 一种普外科治疗痔疮的中药组合物 |
| CN105169018A (zh) * | 2015-09-02 | 2015-12-23 | 江淑芬 | 一种普外科治疗痔疮的中药组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048894B (zh) | 一种治疗烧伤的中药组合物及其制备方法 | |
| CN102205026B (zh) | 一种治疗小儿慢性鼻窦炎的中药组合物及其制备方法 | |
| CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN102178804B (zh) | 一种治疗肛周湿疹的中药组合物及其制备方法 | |
| CN102078569B (zh) | 一种治疗肝癌的中药制剂及其制备方法 | |
| CN103860978B (zh) | 一种治疗褥疮的中药制剂及其制备方法 | |
| CN102000164B (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
| CN104524287A (zh) | 一种治疗过敏性紫癜的中药组合物及其制备方法 | |
| CN102178877B (zh) | 一种治疗阴囊湿疹的外用制剂及其制备方法 | |
| CN103520655A (zh) | 一种治疗寻常型银屑病的中药组合物及其制备方法 | |
| CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
| CN104815037A (zh) | 一种治疗风湿蕴毒型慢性湿疹的药物及其制备方法 | |
| CN104147538A (zh) | 一种治疗湿热毒盛型糖尿病足的中药制剂及其制备方法 | |
| CN104042971A (zh) | 用于治疗阴虚毒热型肺癌的药物组合物及其制备方法 | |
| CN103933405A (zh) | 用于治疗气血两虚型烧伤的药物组合物及其制备方法 | |
| CN104001118A (zh) | 用于治疗湿热浸淫型运动神经元病的药物及其制备方法 | |
| CN105169018A (zh) | 一种普外科治疗痔疮的中药组合物 | |
| CN104667183A (zh) | 治疗湿热邪滞型化脓性骨髓炎的药物制剂及其制备方法 | |
| CN105106634A (zh) | 一种治疗急性阑尾炎的中药制剂及其应用 | |
| CN104324185A (zh) | 一种治疗白带过多的中药组合物及其制备方法 | |
| CN104257871B (zh) | 用于治疗湿热毒蕴型急性网状淋巴管炎的药物组合物及其制备方法 | |
| CN104740405A (zh) | 一种治疗过敏性紫癜性肾损害的中药制剂及制备方法 | |
| CN103933359A (zh) | 用于祛除瘢痕疙瘩的药物组合物及其制备方法 | |
| CN105169277A (zh) | 一种保肝利胆的栀子口服液及其制备方法 | |
| CN105169111A (zh) | 一种用于治疗慢性荨麻疹的中药组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141105 |